Acadia Pharmaceuticals Inc. (ACAD) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ACAD SEC filings page.
Acadia Pharmaceuticals Inc. (ACAD) reported $1.1B in revenue over the twelve months to Jun 30, 2026, up 11.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Acadia's business now generates cash, but FY2025 earnings were lifted by a large tax benefit as operating profit weakened.
FY2025 net income reached$391M while operating cash flow was only$110M , showing that reported profit did not convert proportionally into cash. The gap is consistent with a$252M tax benefit, so headline earnings do not represent equivalent operating momentum.
Gross margin was essentially unchanged at
Liabilities fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Acadia Pharmaceuticals Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Acadia Pharmaceuticals Inc. has an operating margin of 9.8%, meaning the company retains $10 of operating profit per $100 of revenue. This results in a moderate score of 52/100, indicating healthy but not exceptional operating efficiency. This is down from 24.1% the prior year.
Acadia Pharmaceuticals Inc.'s revenue grew 11.9% year-over-year to $1.1B, a solid pace of expansion. This earns a growth score of 83/100.
Acadia Pharmaceuticals Inc. carries a low D/E ratio of 0.27, meaning only $0.27 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 71/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.83, Acadia Pharmaceuticals Inc. holds $3.83 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 86/100.
Acadia Pharmaceuticals Inc. converts 9.8% of revenue into free cash flow ($105.1M). This strong cash generation earns a score of 66/100.
Acadia Pharmaceuticals Inc.'s ROE of 31.9% shows moderate profitability relative to equity, earning a score of 50/100. This is up from 30.8% the prior year.
Acadia Pharmaceuticals Inc. scores 5.60, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.2B) relative to total liabilities ($336.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Acadia Pharmaceuticals Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Acadia Pharmaceuticals Inc. generates $0.28 in operating cash flow ($109.8M OCF vs $391.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Acadia Pharmaceuticals Inc. generated $308.0M in revenue in Q2 2026. This represents an increase of 16.4% from the same quarter a year earlier. Against the prior quarter it is up 14.9%.
Acadia Pharmaceuticals Inc.'s EBITDA was $41.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.1% from the same quarter a year earlier. Against the prior quarter it is up 2625.8%.
Acadia Pharmaceuticals Inc. reported $31.5M in net income in Q2 2026. This represents an increase of 18.1% from the same quarter a year earlier. Against the prior quarter it is up 766.1%.
Acadia Pharmaceuticals Inc. earned $0.18 per diluted share (EPS) in Q2 2026. This represents an increase of 12.5% from the same quarter a year earlier. Against the prior quarter it is up 800.0%.
Cash & Balance Sheet
Acadia Pharmaceuticals Inc. generated $95.7M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 50.3% from the same quarter a year earlier. Against the prior quarter it is up 232.6%.
Acadia Pharmaceuticals Inc. held $385.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Acadia Pharmaceuticals Inc.'s gross margin was 90.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.
Acadia Pharmaceuticals Inc.'s operating margin was 12.3% in Q2 2026, reflecting core business profitability. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 14.0 percentage points.
Acadia Pharmaceuticals Inc.'s net profit margin was 10.2% in Q2 2026, showing the share of revenue converted to profit. This is up 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.9 percentage points.
Acadia Pharmaceuticals Inc.'s ROE was 2.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.1 percentage points.
Capital Allocation
Acadia Pharmaceuticals Inc. invested $81.6M in research and development in Q2 2026. This represents an increase of 4.6% from the same quarter a year earlier. Against the prior quarter it is up 6.1%.
Acadia Pharmaceuticals Inc. invested $5.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 1613.5% from the same quarter a year earlier. Against the prior quarter it is down 2.4%.
Not reported for Q2 2026.
ACAD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $308.0M+16.4% | $268.1M+9.7% | $284.0M+9.4% | $278.6M+11.3% | $264.6M+9.3% | $244.3M+18.7% | $259.6M+12.4% | $250.4M+18.3% |
| Cost of Revenue | $28.3M+36.6% | $24.8M+21.6% | $26.2M+20.3% | $21.6M+14.8% | $20.7M+13.7% | $20.4M-11.1% | $21.8M | $18.9M+29.0% |
| Gross Profit | $279.6M+14.7% | $243.3M+8.6% | $257.8M+8.4% | $257.0M+11.0% | $243.8M+9.0% | $223.9M+22.4% | $237.8M+11.6% | $231.5M+17.5% |
| R&D Expenses | $81.6M+4.6% | $76.9M-1.8% | $84.8M-15.9% | $87.8M+31.9% | $78.0M+2.3% | $78.3M+31.1% | $100.7M | $66.6M-57.6% |
| SG&A Expenses | $160.3M+20.0% | $171.0M+35.3% | $155.6M+19.6% | $133.4M+0.1% | $133.5M+14.0% | $126.4M+17.0% | $130.1M | $133.3M+36.2% |
| Operating Income | $37.8M+16.9% | -$4.6M-123.9% | $17.4M-88.7% | $35.8M+13.0% | $32.4M+6.4% | $19.3M+26.8% | $153.5M | $31.6M+154.8% |
| EBITDA | $41.0M+16.1% | -$1.6M-107.3% | $20.3M-87.2% | $38.7M+13.1% | $35.3M+7.0% | $22.2M+7.2% | $158.7M | $34.2M+161.0% |
| Income Tax | $15.0M+10.5% | $344K-96.1% | -$247.2M-1525.6% | -$27.2M-550.0% | $13.5M+257.1% | $8.8M+97.7% | $17.3M | $6.0M-53.6% |
| Net Income | $31.5M+18.1% | $3.6M-80.8% | $273.6M+90.9% | $71.8M+119.1% | $26.7M-20.1% | $19.0M+14.7% | $143.3M+212.9% | $32.8M+150.3% |
| EPS (Basic) | $0.18+12.5% | $0.02-81.8% | $1.62+86.2% | $0.43+115.0% | $0.16-20.0% | $0.11+10.0% | $0.87+210.7% | $0.20+150.0% |
| EPS (Diluted) | $0.18+12.5% | $0.02-81.8% | $1.61+87.2% | $0.42+110.0% | $0.16-20.0% | $0.11+10.0% | $0.86+207.1% | $0.20+150.0% |
| Diluted Shares (Avg) | 173M+2.5% | 173M+3.0% | N/A | 171M+2.7% | 169M+1.5% | 168M+0.6% | N/A | 166M+1.2% |
Not reported in any period shown, so not listed: Interest Expense.
ACAD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.7B+42.2% | $1.6B+41.8% | $1.6B+31.7% | $1.3B+36.2% | $1.2B+34.1% | $1.1B+32.4% | $1.2B+58.6% | $976.9M+54.4% |
| Current Assets | $1.2B+27.5% | $1.1B+25.8% | $1.1B+13.2% | $1.1B+36.6% | $960.6M+31.8% | $870.9M+29.0% | $938.3M+52.3% | $788.3M+57.9% |
| Cash & Equivalents | $385.0M+51.8% | $282.2M+29.6% | $177.7M-44.4% | $258.0M+66.3% | $253.6M+43.2% | $217.7M+6.3% | $319.6M+69.4% | $155.1M+58.0% |
| Short-Term Investments | $571.5M+12.4% | $569.2M+22.7% | $642.0M+47.1% | $589.0M+43.6% | $508.4M+57.0% | $463.9M+74.5% | $436.4M+74.4% | $410.2M+65.6% |
| Inventory | $108.7M-1.7% | $112.3M+9.1% | $111.4M+21.5% | $106.0M+22.2% | $110.5M+28.4% | $103.0M+54.5% | $91.7M+126.7% | $86.7M+241.5% |
| Accounts Receivable | $150.6M+40.1% | $135.3M+28.0% | $121.5M+23.0% | $115.8M+18.0% | $107.5M+3.7% | $105.7M+11.7% | $98.7M+0.5% | $98.2M+5.8% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $436.3M+8.2% | $357.2M-2.7% | $336.8M-26.0% | $413.5M+3.5% | $403.2M+1.5% | $367.1M-6.1% | $455.0M+43.4% | $399.7M+47.8% |
| Current Liabilities | $361.4M+9.5% | $305.5M+1.0% | $277.1M-29.8% | $356.6M+3.7% | $330.0M-2.3% | $302.5M-8.5% | $394.9M+55.3% | $343.9M+64.1% |
| Non-Current Liabilities | $74.9M+2.3% | $51.6M-20.1% | $59.7M-0.7% | $56.9M+2.1% | $73.1M+22.8% | $64.6M+6.8% | $60.1M-4.5% | $55.7M-8.3% |
| Total Equity | $1.3B+58.9% | $1.2B+63.1% | $1.2B+67.5% | $917.3M+58.9% | $822.4M+59.2% | $765.2M+64.9% | $732.8M+69.7% | $577.2M+59.4% |
| Retained Earnings | -$1.8B+17.6% | -$1.8B+17.2% | -$1.8B+17.7% | -$2.1B+11.1% | -$2.2B+9.3% | -$2.2B+9.5% | -$2.2B+9.3% | -$2.3B+5.2% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
ACAD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $100.8M+57.6% | $34.0M+67.2% | -$48.7M-220.7% | $74.3M+17.5% | $64.0M+155.7% | $20.3M-30.1% | $40.4M-52.7% | $63.2M+207.3% |
| Depreciation & Amortization | $3.2M+7.6% | $3.0M+1.4% | $2.9M-43.9% | $3.0M+14.8% | $2.9M+14.2% | $3.0M-46.6% | $5.2M+218.5% | $2.6M+49.2% |
| Stock-Based Compensation | $16.9M+18.1% | $14.7M+29.2% | N/A | $13.2M-49.6% | $14.3M-8.6% | $11.4M-22.8% | N/A | $26.2M+41.1% |
| Capital Expenditures | $5.1M+1613.5% | $5.2M | $4.0M+784.1% | $388K+454.3% | $297K | $0 | $453K | $70K |
| Free Cash Flow | $95.7M+50.3% | $28.8M+41.6% | -$52.7M-232.1% | $73.9M+17.0% | $63.7M | $20.3M | $39.9M-53.2% | $63.2M |
| Investing Cash Flow | -$8.5M+80.3% | $66.3M+153.4% | -$55.9M-145.7% | -$79.4M+3.8% | -$43.3M+23.0% | -$124.0M-783.6% | $122.2M+35301.7% | -$82.5M-341.7% |
| Financing Cash Flow | $10.5M-34.2% | $4.2M+130.2% | $22.7M+1051.1% | $9.4M+3416.0% | $16.0M+347.6% | $1.8M+76.2% | $2.0M-63.8% | $268K-97.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ACAD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.8%-1.3pp | 90.8%-0.9pp | 90.8%-0.8pp | 92.2%-0.2pp | 92.2%-0.3pp | 91.6%+2.8pp | 91.6%-0.7pp | 92.5%-0.6pp |
| Operating Margin | 12.3%+0.1pp | -1.7%-9.6pp | 6.1%-53.0pp | 12.8%+0.2pp | 12.2%-0.3pp | 7.9%+0.5pp | 59.1% | 12.6%+39.9pp |
| Net Margin | 10.2%+0.2pp | 1.4%-6.4pp | 96.3%+41.1pp | 25.8%+12.7pp | 10.1%-3.7pp | 7.8%-0.3pp | 55.2%+35.4pp | 13.1%+43.9pp |
| Return on Equity | 2.4%-0.8pp | 0.3%-2.2pp | 22.3%+2.7pp | 7.8%+2.1pp | 3.2%-3.2pp | 2.5%-1.1pp | 19.6%+8.9pp | 5.7%+23.7pp |
| Return on Assets | 1.8%-0.4pp | 0.2%-1.4pp | 17.5%+5.4pp | 5.4%+2.0pp | 2.2%-1.5pp | 1.7%-0.3pp | 12.1%+5.9pp | 3.4%+13.7pp |
| Current Ratio | 3.39+0.5x | 3.59+0.7x | 3.83+1.5x | 3.02+0.7x | 2.91+0.8x | 2.88+0.8x | 2.380.0x | 2.29-0.1x |
| Debt-to-Equity | 0.33-0.2x | 0.29-0.2x | 0.27-0.3x | 0.45-0.2x | 0.49-0.3x | 0.48-0.4x | 0.62-0.1x | 0.69-0.1x |
| Asset Turnover | 0.180.0x | 0.170.0x | 0.180.0x | 0.210.0x | 0.220.0x | 0.220.0x | 0.22-0.1x | 0.26-0.1x |
| FCF Margin | 31.1%+7.0pp | 10.7%+2.4pp | -18.6%-34.0pp | 26.5%+1.3pp | 24.1% | 8.3% | 15.4%-21.6pp | 25.2% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc. ACAD | FY2025 | $1.1B | $391.0M | 36.5% | $3.2B | 68/100 |
| Metsera, Inc. MTSR | FY2024 | N/A | -$209.1M | N/A | $7.4B | — |
| Arcellx, Inc. ACLX | FY2025 | $22.3M | -$228.9M | N/A | $6.7B | 46/100 |
| Vaxcyte, Inc. PCVX | FY2025 | N/A | -$767K | N/A | $10.5B | — |
| Krystal Biotech, Inc. KRYS | FY2025 | $389.1M | $204.8M | 52.6% | $9.5B | 59/100 |
| Arrowhead Research Corporation ARWR | FY2025 | $829.4M | -$1.6M | -0.2% | $8.2B | 78/100 |
Where Acadia Pharmaceuticals Inc. Ranks
Frequently Asked Questions
What is Acadia Pharmaceuticals Inc.'s annual revenue?
Acadia Pharmaceuticals Inc. (ACAD) reported $1.1B in total revenue for fiscal year 2025. This represents a 11.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Acadia Pharmaceuticals Inc.'s revenue growing?
Acadia Pharmaceuticals Inc. (ACAD) revenue grew by 11.9% year-over-year, from $957.8M to $1.1B in fiscal year 2025.
Is Acadia Pharmaceuticals Inc. profitable?
Yes, Acadia Pharmaceuticals Inc. (ACAD) reported a net income of $391.0M in fiscal year 2025, with a net profit margin of 36.5%.
What is Acadia Pharmaceuticals Inc.'s EBITDA?
Acadia Pharmaceuticals Inc. (ACAD) had EBITDA of $116.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Acadia Pharmaceuticals Inc.'s gross margin?
Acadia Pharmaceuticals Inc. (ACAD) had a gross margin of 91.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Acadia Pharmaceuticals Inc.'s operating margin?
Acadia Pharmaceuticals Inc. (ACAD) had an operating margin of 9.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Acadia Pharmaceuticals Inc.'s net profit margin?
Acadia Pharmaceuticals Inc. (ACAD) had a net profit margin of 36.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Acadia Pharmaceuticals Inc.'s return on equity (ROE)?
Acadia Pharmaceuticals Inc. (ACAD) has a return on equity of 31.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Acadia Pharmaceuticals Inc.'s free cash flow?
Acadia Pharmaceuticals Inc. (ACAD) generated $105.1M in free cash flow during fiscal year 2025. This represents a -33.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Acadia Pharmaceuticals Inc.'s operating cash flow?
Acadia Pharmaceuticals Inc. (ACAD) generated $109.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Acadia Pharmaceuticals Inc.'s total assets?
Acadia Pharmaceuticals Inc. (ACAD) had $1.6B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Acadia Pharmaceuticals Inc.'s capital expenditures?
Acadia Pharmaceuticals Inc. (ACAD) invested $4.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Acadia Pharmaceuticals Inc. spend on research and development?
Acadia Pharmaceuticals Inc. (ACAD) invested $328.8M in research and development during fiscal year 2025.
What is Acadia Pharmaceuticals Inc.'s current ratio?
Acadia Pharmaceuticals Inc. (ACAD) had a current ratio of 3.83 as of fiscal year 2025, which is generally considered healthy.
What is Acadia Pharmaceuticals Inc.'s debt-to-equity ratio?
Acadia Pharmaceuticals Inc. (ACAD) had a debt-to-equity ratio of 0.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Acadia Pharmaceuticals Inc.'s return on assets (ROA)?
Acadia Pharmaceuticals Inc. (ACAD) had a return on assets of 25.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Acadia Pharmaceuticals Inc.'s P/E ratio?
Acadia Pharmaceuticals Inc. (ACAD) trades at 8.4x earnings, its market capitalization divided by net income of $380.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $3.2B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Acadia Pharmaceuticals Inc.'s price-to-sales ratio?
Acadia Pharmaceuticals Inc. (ACAD) trades at 2.8x sales, its market capitalization divided by revenue of $1.1B revenue, trailing 12 months to June 30, 2026. The market capitalization is $3.2B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Acadia Pharmaceuticals Inc.'s Altman Z-Score?
Acadia Pharmaceuticals Inc. (ACAD) has an Altman Z-Score of 5.60, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Acadia Pharmaceuticals Inc.'s Piotroski F-Score?
Acadia Pharmaceuticals Inc. (ACAD) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Acadia Pharmaceuticals Inc.'s earnings high quality?
Acadia Pharmaceuticals Inc. (ACAD) has an earnings quality ratio of 0.28x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Acadia Pharmaceuticals Inc.?
Acadia Pharmaceuticals Inc. (ACAD) scores 68 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.